[PDF][PDF] Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

B Peng, M Hayes, D Resta… - Journal of clinical …, 2004 - researchgate.net
B Peng, M Hayes, D Resta, A Racine-Poon, BJ Druker, M Talpaz, CL Sawyers, M Rosamilia…
Journal of clinical oncology, 2004researchgate.net
Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid
Leukemia Patients Page 1 Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I
Trial With Chronic Myeloid Leukemia Patients Bin Peng, Michael Hayes, Debra Resta, Amy
Racine-Poon, Brian J. Druker, Moshe Talpaz, Charles L. Sawyers, Marianne Rosamilia, John
Ford, Peter Lloyd, and Renaud Capdeville A B S T R A C T Purpose To evaluate the basic
pharmacokinetic (PK) characteristics of imatinib mesylate and assess the relationship …
Purpose
To evaluate the basic pharmacokinetic (PK) characteristics of imatinib mesylate and assess the relationship between the PK and pharmacodynamic (PD) properties of the drug.
researchgate.net